The 10-day RSI Indicator for PLRX moved out of overbought territory on December 03, 2024. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 instances where the indicator moved out of the overbought zone. In of the 24 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
The Momentum Indicator moved below the 0 level on December 13, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on PLRX as a result. In of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PLRX turned negative on December 13, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
PLRX moved below its 50-day moving average on December 18, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PLRX crossed bearishly below the 50-day moving average on December 20, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PLRX broke above its upper Bollinger Band on December 02, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 50-day moving average for PLRX moved above the 200-day moving average on December 03, 2024. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PLRX advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 94 cases where PLRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PLRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.325) is normal, around the industry mean (14.529). P/E Ratio (0.000) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). PLRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). PLRX's P/S Ratio (3333.333) is very high in comparison to the industry average of (255.281).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PLRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a company which engages in the business of developing and commercializing novel therapies for fibrotic diseases
Industry Biotechnology
A.I.dvisor indicates that over the last year, PLRX has been loosely correlated with NTLA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if PLRX jumps, then NTLA could also see price increases.
Ticker / NAME | Correlation To PLRX | 1D Price Change % | ||
---|---|---|---|---|
PLRX | 100% | -0.68% | ||
NTLA - PLRX | 52% Loosely correlated | +0.83% | ||
RCKT - PLRX | 50% Loosely correlated | +1.85% | ||
CRSP - PLRX | 50% Loosely correlated | +0.83% | ||
BEAM - PLRX | 50% Loosely correlated | +8.04% | ||
PRME - PLRX | 49% Loosely correlated | +3.94% | ||
More |